Mark S. Segal MD, PhD

Dr. Segal received a B.S. degree in Biology from MIT in 1984. As an undergraduate, he did research in the laboratory of Dr. Monty Krieger studying the alteration in the glycosylation pattern of a cell line defective in LDL receptor endocytosis. After graduating from MIT, Dr. Segal was accepted into the MSTP M.D./Ph.D. training program at the University of Texas Southwestern Medical School. He did his Ph.D. dissertation work in the laboratories of Dr. Mary-Jane Gething and Dr. Joseph Sambrook. He studied the folding pattern of the influenza hemagglutinin protein and its interaction with the heat shock protein BiP.

After graduating from the M.D./Ph.D. program in 1992, he completed both his internship and residency in Internal Medicine at Parkland Memorial Hospital at Dallas. In 1995, he started his nephrology fellowship at Beth Israel Hospital under the direction of Dr. Vikas Sukhatme. During his fellowship, he worked on a developing a gene therapy vector consisting of a newly created lentiviral vector combined with an adenoviral vector to yield a novel method for gene transduction into the kidney.

For this work, he was awarded an NIH KO8. In addition, Dr. Segal worked on investigating the mechanism by which endostatin, an anti-angiogenic compound, is completely selective for endothelial cells in tumor vascular beds. After one year as an Instructor at Harvard Medical School, he joined the Department of Medicine at the University of Florida as an Assistant Professor. In 2008, he was promoted to Associate Professor with tenure. In 2010 he was appointed Chief of the Division of Nephrology, Hypertension, and Renal Transplantation.